<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00910</drugbank-id>
  <drugbank-id>APRD01165</drugbank-id>
  <name>Paricalcitol</name>
  <description>Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.</description>
  <cas-number>131918-61-1</cas-number>
  <unii>6702D36OG5</unii>
  <average-mass>416.6365</average-mass>
  <monoisotopic-mass>416.329045274</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Anchel Schwartz, Alexei Ploutno, Koby Wolfman, "Preparation of paricalcitol." U.S. Patent US20070149489, issued June 28, 2007.</synthesis-reference>
  <indication>For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4</indication>
  <pharmacodynamics>Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin and from dietary intake. Vitamin D requires two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol [1,25(OH)2 D3], is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis.1 Decreased levels of 1,25(OH)2 D3 have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH)2 D3 and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy. An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A at concentrations up to 50 nM (21 ng/mL).</pharmacodynamics>
  <mechanism-of-action>Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.</mechanism-of-action>
  <toxicity/>
  <metabolism>Metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4</metabolism>
  <absorption>Well absorbed</absorption>
  <half-life>4 to 6 hours</half-life>
  <protein-binding>99.8% (bound to plasma proteins)</protein-binding>
  <route-of-elimination>Paricalcitol is excreted primarily by hepatobiliary excretion.</route-of-elimination>
  <volume-of-distribution>* 30.8 ± 7.5 L [CKD Stage 5-HD]&#13;
* 34.9 ± 9.5 L [CKD Stage 5-PD]&#13;
* 23.8 L [healthy subjects]</volume-of-distribution>
  <clearance>* 1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis]&#13;
* 1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.</description>
    <direct-parent>Vitamin D and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Vitamin D and derivatives</subclass>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <alternative-parent>Triterpenoids</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary alcohol</substituent>
    <substituent>Triterpenoid</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">19-Nor-1alpha,25-dihydroxyvitamin D2</synonym>
    <synonym language="english" coder="inn/usan">Paricalcitol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Paricalcitol</name>
      <labeller>Banner Pharmacaps</labeller>
      <ndc-id/>
      <ndc-product-code>10888-5001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Banner Pharmacaps</labeller>
      <ndc-id/>
      <ndc-product-code>10888-5002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Banner Pharmacaps</labeller>
      <ndc-id/>
      <ndc-product-code>10888-5003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Banner Life Sciences Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>69387-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Banner Life Sciences Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>69387-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Banner Life Sciences Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>69387-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Rising Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64980-225</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Rising Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64980-226</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Rising Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64980-227</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-31</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090829</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091412</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-664</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091412</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-665</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091412</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA207692</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on>2017-04-30</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090829</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7657</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090829</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7658</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090829</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-078</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-23</started-marketing-on>
      <ended-marketing-on>2017-01-02</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-079</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-23</started-marketing-on>
      <ended-marketing-on>2017-01-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on>2017-01-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>MARKSANS PHARMA LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code>25000-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>MARKSANS PHARMA LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code>25000-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>MARKSANS PHARMA LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code>25000-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-478</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-836</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-9625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA205917</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-9624</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA205917</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-9596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA205917</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Lotus Pharmaceutical Co., Ltd. Nantou Plant</labeller>
      <ndc-id/>
      <ndc-product-code>40051-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Lotus Pharmaceutical Co., Ltd. Nantou Plant</labeller>
      <ndc-id/>
      <ndc-product-code>40051-613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Lotus Pharmaceutical Co., Ltd. Nantou Plant</labeller>
      <ndc-id/>
      <ndc-product-code>40051-614</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-379</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-389</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr. Reddy's Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43598-563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA204910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr. Reddy's Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43598-564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA204910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr. Reddy's Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43598-562</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA204910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Dr. Reddy's Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43598-565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA204910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206699</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206699</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1035</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 ug/2mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206699</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 ug/2mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206699</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>TIME CAP LABORATORIES, INC</labeller>
      <ndc-id/>
      <ndc-product-code>49483-689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>TIME CAP LABORATORIES, INC</labeller>
      <ndc-id/>
      <ndc-product-code>49483-688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>TIME CAP LABORATORIES, INC</labeller>
      <ndc-id/>
      <ndc-product-code>49483-687</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>AuroMedics Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55150-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>AuroMedics Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55150-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>AuroMedics Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55150-214</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 ug/2mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>AuroMedics Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55150-215</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 ug/2mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA207174</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA207174</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-266</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-14</started-marketing-on>
      <ended-marketing-on>2020-08-03</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-267</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-14</started-marketing-on>
      <ended-marketing-on>2020-04-23</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Zydus Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68382-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-1008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA201657</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-1007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA201657</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207672</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-937</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207672</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-938</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207672</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202539</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-823</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Paricalcitol</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6971</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-26</started-marketing-on>
      <ended-marketing-on>2018-07-20</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>Abbott Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0074-4315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-12</started-marketing-on>
      <ended-marketing-on>2006-07-12</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>4 ug/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-4314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-14</started-marketing-on>
      <ended-marketing-on>2019-12-30</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-4317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-14</started-marketing-on>
      <ended-marketing-on>2014-09-03</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-9036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-9037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>2 ug/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-4637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020819</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>AbbVie Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0074-1658</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020819</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zemplar</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02266202</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-01</started-marketing-on>
      <ended-marketing-on>2012-11-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mcg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Paricalcitol</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
    <mixture>
      <name>Zemplar</name>
      <ingredients>Paricalcitol</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Abbott Laboratories Ltd.</name>
      <url>http://www.abbott.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Abbott laboratories pharmaceutical products div</manufacturer>
    <manufacturer generic="false" url="">Abbott laboratories</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Zemplar 1 mcg capsule</description>
      <cost currency="USD">9.39</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Zemplar 2 mcg/ml vial</description>
      <cost currency="USD">11.22</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Zemplar 2 mcg capsule</description>
      <cost currency="USD">18.79</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Zemplar 5 mcg/ml vial</description>
      <cost currency="USD">28.03</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Zemplar 4 mcg capsule</description>
      <cost currency="USD">37.58</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Anti-Parathyroid Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bone Density Conservation Agents</category>
      <mesh-id>D050071</mesh-id>
    </category>
    <category>
      <category>Calcium Homeostasis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cholestanes</category>
      <mesh-id>D002776</mesh-id>
    </category>
    <category>
      <category>Cholestenes</category>
      <mesh-id>D002782</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Membrane Lipids</category>
      <mesh-id>D008563</mesh-id>
    </category>
    <category>
      <category>Secosteroids</category>
      <mesh-id>D012632</mesh-id>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
    <category>
      <category>Sterols</category>
      <mesh-id>D013261</mesh-id>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT1A4 substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vitamin D and Analogues</category>
      <mesh-id>D004100</mesh-id>
    </category>
    <category>
      <category>Vitamins</category>
      <mesh-id>D014815</mesh-id>
    </category>
    <category>
      <category>Vitamins (Fat Soluble)</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>1 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>2 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>4 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>4 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>1 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>2 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength>4 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>2 ug/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>4 ug/1</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>10 ug/2mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>2 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>5 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>2 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>1 ug/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 mcg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="H05BX02">
      <level code="H05BX">Other anti-parathyroid agents</level>
      <level code="H05B">ANTI-PARATHYROID AGENTS</level>
      <level code="H05">CALCIUM HOMEOSTASIS</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00910.pdf?1265922805</fda-label>
  <patents>
    <patent>
      <number>5246925</number>
      <country>United States</country>
      <approved>1993-09-21</approved>
      <expires>2012-04-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5597815</number>
      <country>United States</country>
      <approved>1997-01-28</approved>
      <expires>2016-01-13</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6361758</number>
      <country>United States</country>
      <approved>2002-03-26</approved>
      <expires>2018-10-08</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6136799</number>
      <country>United States</country>
      <approved>2000-10-24</approved>
      <expires>2018-10-08</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>Danazol may increase the hypercalcemic activities of Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The serum concentration of Magnesium sulfate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The serum concentration of Magnesium oxide can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The serum concentration of Magnesium salicylate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The serum concentration of Magaldrate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The serum concentration of Magnesium hydroxide can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The serum concentration of Magnesium trisilicate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>The serum concentration of Magnesium chloride can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The serum concentration of Magnesium carbonate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09511</drugbank-id>
      <name>Talc</name>
      <description>The serum concentration of Talc can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The serum concentration of Magnesium citrate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The serum concentration of Magnesium silicate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The serum concentration of Hydrotalcite can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>The serum concentration of Magnesium aspartate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The serum concentration of Magnesium peroxide can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>The serum concentration of Magnesium gluconate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>The serum concentration of Magnesium orotate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The serum concentration of Magnesium can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14514</drugbank-id>
      <name>Magnesium levulinate</name>
      <description>The serum concentration of Magnesium levulinate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14515</drugbank-id>
      <name>Magnesium lactate</name>
      <description>The serum concentration of Magnesium lactate can be increased when it is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01083</drugbank-id>
      <name>Orlistat</name>
      <description>Orlistat can cause a decrease in the absorption of Paricalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Oleandrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Cymarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Proscillaridin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Metildigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Peruvoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>Mineral oil can cause a decrease in the absorption of Paricalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of hypercalcemia can be increased when Diazoxide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The risk or severity of adverse effects can be increased when Calcitriol is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00146</drugbank-id>
      <name>Calcifediol</name>
      <description>The risk or severity of adverse effects can be increased when Calcifediol is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00153</drugbank-id>
      <name>Ergocalciferol</name>
      <description>The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01070</drugbank-id>
      <name>Dihydrotachysterol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01436</drugbank-id>
      <name>Alfacalcidol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Alfacalcidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04258</drugbank-id>
      <name>Seocalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Seocalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04796</drugbank-id>
      <name>Inecalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Inecalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04891</drugbank-id>
      <name>Becocalcidiol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05295</drugbank-id>
      <name>Eldecalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Eldecalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06117</drugbank-id>
      <name>1alpha,24S-Dihydroxyvitamin D2</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha,24S-Dihydroxyvitamin D2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06194</drugbank-id>
      <name>Elocalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Elocalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06272</drugbank-id>
      <name>Maxacalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Maxacalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06410</drugbank-id>
      <name>Doxercalciferol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Doxercalciferol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11094</drugbank-id>
      <name>Vitamin D</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Vitamin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13097</drugbank-id>
      <name>1alpha-Hydroxyvitamin D5</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha-Hydroxyvitamin D5.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13689</drugbank-id>
      <name>Tacalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Tacalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium acetate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00326</drugbank-id>
      <name>Calcium glucoheptonate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium glucoheptonate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>The risk or severity of adverse effects can be increased when Calcium is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13142</drugbank-id>
      <name>Calcium glubionate anhydrous</name>
      <description>The risk or severity of adverse effects can be increased when Calcium glubionate anhydrous is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13231</drugbank-id>
      <name>Calcium lactate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13365</drugbank-id>
      <name>Calcium lactate gluconate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13590</drugbank-id>
      <name>Calcium pangamate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13800</drugbank-id>
      <name>Calcium levulinate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium levulinate is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>The risk or severity of adverse effects can be increased when Calcium cation is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Paricalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00658</drugbank-id>
      <name>Sevelamer</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Sevelamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of hypokalemia can be increased when Paricalcitol is combined with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of hypokalemia can be increased when Paricalcitol is combined with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of hypokalemia can be increased when Paricalcitol is combined with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The risk or severity of hypokalemia can be increased when Paricalcitol is combined with Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The risk or severity of hypokalemia can be increased when Paricalcitol is combined with Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Paricalcitol can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Paricalcitol can be decreased when combined with Eltrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Paricalcitol can be decreased when it is combined with Pitolisant.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.27</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.80e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.26</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>paricalcitol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>416.6365</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>416.329045274</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C27H44O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BPKAHTKRCLCHEA-UBFJEZKGSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>60.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>127.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>51.06</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>4.5</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13272</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>7931</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5281104</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505780</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C08127</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00930</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4444552</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>233195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450798</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000211</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Paricalcitol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200622</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic4/zemplar_caps.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/paricalcitol.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000779</id>
      <name>Vitamin D3 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5880</ref-id>
            <pubmed-id>16076355</pubmed-id>
            <citation>Andress DL: Vitamin D treatment in chronic kidney disease. Semin Dial. 2005 Jul-Aug;18(4):315-21.</citation>
          </article>
          <article>
            <ref-id>A5881</ref-id>
            <pubmed-id>19494617</pubmed-id>
            <citation>Brancaccio D, Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M: New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. Contrib Nephrol. 2009;163:219-26. doi: 10.1159/000223802. Epub 2009 Jun 3.</citation>
          </article>
          <article>
            <ref-id>A5882</ref-id>
            <pubmed-id>20204178</pubmed-id>
            <citation>Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol. 2010;2010:621687. doi: 10.1155/2010/621687. Epub 2010 Mar 2.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P11473" source="Swiss-Prot">
        <name>Vitamin D3 receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.</specific-function>
        <gene-name>VDR</gene-name>
        <locus>12q13.11</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.5</theoretical-pi>
        <molecular-weight>48288.64</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12679</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>VDR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03258</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>340203</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11473</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>VDR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,25-dihydroxyvitamin D3 receptor</synonym>
          <synonym>NR1I1</synonym>
          <synonym>Nuclear receptor subfamily 1 group I member 1</synonym>
          <synonym>VDR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001554|Vitamin D3 receptor
MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTC
PFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSL
RPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSG
DSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQK
VIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDV
TKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLS
NTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLE
VFGNEIS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010550|Vitamin D3 receptor (VDR)
ATGGAGGCAATGGCGGCCAGCACTTCCCTGCCTGACCCTGGAGACTTTGACCGGAACGTG
CCCCGGATCTGTGGGGTGTGTGGAGACCGAGCCACTGGCTTTCACTTCAATGCTATGACC
TGTGAAGGCTGCAAAGGCTTCTTCAGGCGAAGCATGAAGCGGAAGGCACTATTCACCTGC
CCCTTCAACGGGGACTGCCGCATCACCAAGGACAACCGACGCCACTGCCAGGCCTGCCGG
CTCAAACGCTGTGTGGACATCGGCATGATGAAGGAGTTCATTCTGACAGATGAGGAAGTG
CAGAGGAAGCGGGAGATGATCCTGAAGCGGAAGGAGGAGGAGGCCTTGAAGGACAGTCTG
CGGCCCAAGCTGTCTGAGGAGCAGCAGCGCATCATTGCCATACTGCTGGACGCCCACCAT
AAGACCTACGACCCCACCTACTCCGACTTCTGCCAGTTCCGGCCTCCAGTTCGTGTGAAT
GATGGTGGAGGGAGCCATCCTTCCAGGCCCAACTCCAGACACACTCCCAGCTTCTCTGGG
GACTCCTCCTCCTCCTGCTCAGATCACTGTATCACCTCTTCAGACATGATGGACTCGTCC
AGCTTCTCCAATCTGGATCTGAGTGAAGAAGATTCAGATGACCCTTCTGTGACCCTAGAG
CTGTCCCAGCTCTCCATGCTGCCCCACCTGGCTGACCTGGTCAGTTACAGCATCCAAAAG
GTCATTGGCTTTGCTAAGATGATACCAGGATTCAGAGACCTCACCTCTGAGGACCAGATC
GTACTGCTGAAGTCAAGTGCCATTGAGGTCATCATGTTGCGCTCCAATGAGTCCTTCACC
ATGGACGACATGTCCTGGACCTGTGGCAACCAAGACTACAAGTACCGCGTCAGTGACGTG
ACCAAAGCCGGACACAGCCTGGAGCTGATTGAGCCCCTCATCAAGTTCCAGGTGGGACTG
AAGAAGCTGAACTTGCATGAGGAGGAGCATGTCCTGCTCATGGCCATCTGCATCGTCTCC
CCAGATCGTCCTGGGGTGCAGGACGCCGCGCTGATTGAGGCCATCCAGGACCGCCTGTCC
AACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCACCTGCTCTAT
GCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAG
TACCGCTGCCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAA
GTGTTTGGCAATGAGATCTCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>RNA polymerase II transcription factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcitriol binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcitriol receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lithocholic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lithocholic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoid X receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>decidualization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland branching involved in pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of keratinocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process involved in mammary gland involution</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcidiol 1-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002250</id>
      <name>1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14909</ref-id>
            <pubmed-id>15733015</pubmed-id>
            <citation>Robinson DM, Scott LJ: Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs. 2005;65(4):559-76.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q07973" source="Swiss-Prot">
        <name>1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial</name>
        <general-function>Oxidoreductase activity</general-function>
        <specific-function>Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23-hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.</specific-function>
        <gene-name>CYP24A1</gene-name>
        <locus>20q13</locus>
        <cellular-location>Mitochondrion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.99</theoretical-pi>
        <molecular-weight>58874.695</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2602</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP24A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L13286</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>306704</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1365</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07973</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP24A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.126</synonym>
          <synonym>24-OHase</synonym>
          <synonym>CYP24</synonym>
          <synonym>Cytochrome P450 24A1</synonym>
          <synonym>Cytochrome P450-CC24</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004416|1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
MSSPISKSRSLAAFLQQLRSPRQPPRLVTSTAYTSPQPREVPVCPLTAGGETQNAAALPG
PTSWPLLGSLLQILWKGGLKKQHDTLVEYHKKYGKIFRMKLGSFESVHLGSPCLLEALYR
TESAYPQRLEIKPWKAYRDYRKEGYGLLILEGEDWQRVRSAFQKKLMKPGEVMKLDNKIN
EVLADFMGRIDELCDERGHVEDLYSELNKWSFESICLVLYEKRFGLLQKNAGDEAVNFIM
AIKTMMSTFGRMMVTPVELHKSLNTKVWQDHTLAWDTIFKSVKACIDNRLEKYSQQPSAD
FLCDIYHQNRLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQVQQKLLKEIQSVL
PENQVPRAEDLRNMPYLKACLKESMRLTPSVPFTTRTLDKATVLGEYALPKGTVLMLNTQ
VLGSSEDNFEDSSQFRPERWLQEKEKINPFAHLPFGVGKRMCIGRRLAELQLHLALCWIV
RKYDIQATDNEPVEMLHSGTLVPSRELPIAFCQR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016728|1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)
ATGAGCTCCCCCATCAGCAAGAGCCGCTCGCTTGCCGCCTTCCTGCAGCAGCTGCGCAGT
CCGAGGCAGCCCCCGAGACTGGTGACATCTACGGCGTACACGTCCCCTCAGCCGCGAGAG
GTGCCAGTCTGCCCGCTGACAGCTGGTGGCGAGACTCAGAACGCGGCCGCCCTGCCGGGC
CCCACCAGCTGGCCACTGCTGGGCAGCCTGCTGCAGATTCTCTGGAAAGGGGGTCTCAAG
AAACAGCACGACACCCTGGTGGAGTACCACAAGAAGTATGGCAAGATTTTCCGCATGAAG
TTGGGTTCCTTTGAGTCGGTGCACCTGGGCTCGCCATGCCTGCTGGAAGCGCTGTACCGC
ACCGAGAGCGCGTACCCGCAGCGGCTGGAGATCAAACCGTGGAAGGCCTATCGCGACTAC
CGCAAAGAAGGCTACGGGCTGCTGATCCTGGAAGGGGAAGACTGGCAGCGGGTCCGGAGT
GCCTTTCAAAAGAAACTAATGAAACCAGGGGAAGTGATGAAGCTGGACAACAAAATCAAT
GAGGTCTTGGCCGATTTTATGGGCAGAATAGATGAGCTCTGTGATGAAAGAGGCCACGTT
GAAGACTTGTACAGCGAACTGAACAAATGGTCGTTTGAAAGTATCTGCCTCGTGTTGTAT
GAGAAGAGATTTGGGCTTCTCCAGAAGAATGCAGGGGATGAAGCTGTGAACTTCATCATG
GCCATCAAAACAATGATGAGCACGTTTGGGAGGATGATGGTCACTCCAGTCGAGCTGCAC
AAGAGCCTCAACACCAAGGTCTGGCAGGACCACACTCTGGCCTGGGACACCATTTTCAAA
TCAGTCAAAGCTTGTATCGACAACCGGTTAGAGAAGTATTCTCAGCAGCCTAGTGCAGAT
TTCCTTTGTGACATTTATCACCAGAATCGGCTTTCAAAGAAAGAATTGTATGCTGCTGTC
ACAGAGCTCCAGCTGGCTGCGGTGGAAACGACAGCAAACAGTCTAATGTGGATTCTCTAC
AATTTATCCCGTAATCCCCAAGTGCAACAAAAGCTTCTTAAGGAAATTCAAAGTGTATTA
CCTGAGAATCAGGTGCCACGGGCAGAAGATTTGAGGAATATGCCGTATTTAAAAGCCTGT
CTGAAAGAATCTATGAGGCTTACGCCGAGTGTACCATTTACAACTCGGACTCTTGACAAG
GCAACAGTTCTGGGTGAATATGCTTTACCCAAAGGAACAGTGCTCATGCTAAATACCCAG
GTGTTGGGATCCAGTGAAGACAATTTTGAAGATTCAAGTCAGTTTAGACCTGAACGTTGG
CTTCAGGAGAAGGAAAAAATTAATCCTTTTGCGCATCTTCCATTTGGCGTTGGAAAAAGA
ATGTGCATTGGTCGCCGATTAGCAGAGCTTCAACTGCATTTGGCTCTTTGTTGGATTGTC
CGCAAATACGACATCCAGGCCACAGACAATGAGCCTGTTGAGATGCTACACTCAGGCACC
CTGGTGCCCAGCCGGGAACTCCCCATCGCGTTTTGCCAGCGATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-alpha,25-dihydroxyvitamin D3 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>25-hydroxycholecalciferol-24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin D</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme>
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme>
      <id>BE0003544</id>
      <name>UDP-glucuronosyltransferase 1-4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P22310" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 1-4</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).</specific-function>
        <gene-name>UGT1A4</gene-name>
        <locus>2q37</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions>492-508</transmembrane-regions>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>8.68</theoretical-pi>
        <molecular-weight>60024.535</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12536</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M57951</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>184475</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P22310</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD14_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>Bilirubin-specific UDPGT isozyme 2</synonym>
          <synonym>GNT1</synonym>
          <synonym>hUG-BR2</synonym>
          <synonym>UDP-glucuronosyltransferase 1-D</synonym>
          <synonym>UDP-glucuronosyltransferase 1A4</synonym>
          <synonym>UDPGT 1-4</synonym>
          <synonym>UGT-1D</synonym>
          <synonym>UGT1</synonym>
          <synonym>UGT1D</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006829|UDP-glucuronosyltransferase 1-4
MARGLQVPLPRLATGLLLLLSVQPWAESGKVLVVPTDGSPWLSMREALRELHARGHQAVV
LTPEVNMHIKEEKFFTLTAYAVPWTQKEFDRVTLGYTQGFFETEHLLKRYSRSMAIMNNV
SLALHRCCVELLHNEALIRHLNATSFDVVLTDPVNLCGAVLAKYLSIPAVFFWRYIPCDL
DFKGTQCPNPSSYIPKLLTTNSDHMTFLQRVKNMLYPLALSYICHTFSAPYASLASELFQ
REVSVVDLVSYASVWLFRGDFVMDYPRPIMPNMVFIGGINCANGKPLSQEFEAYINASGE
HGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQND
LLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMT
SEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAH
DLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012467|UDP-glucuronosyltransferase 1-4 (UGT1A4)
ATGGCCAGAGGACTCCAGGTTCCCCTGCCGCGGCTGGCCACAGGACTGCTGCTCCTCCTC
AGTGTCCAGCCCTGGGCTGAGAGTGGAAAGGTGTTGGTGGTGCCCACTGATGGCAGCCCC
TGGCTCAGCATGCGGGAGGCCTTGCGGGAGCTCCATGCCAGAGGCCACCAGGCGGTGGTC
CTCACCCCAGAGGTGAATATGCACATCAAAGAAGAGAAATTTTTCACCCTGACAGCCTAT
GCTGTTCCATGGACCCAGAAGGAATTTGATCGCGTTACGCTGGGCTACACTCAAGGGTTC
TTTGAAACAGAACATCTTCTGAAGAGATATTCTAGAAGTATGGCAATTATGAACAATGTA
TCTTTGGCCCTTCATAGGTGTTGTGTGGAGCTACTGCATAATGAGGCCCTGATCAGGCAC
CTGAATGCTACTTCCTTTGATGTGGTTTTAACAGACCCCGTTAACCTCTGTGGGGCGGTG
CTGGCTAAGTACCTGTCGATTCCTGCTGTGTTTTTTTGGAGGTACATTCCATGTGACTTA
GACTTTAAGGGCACACAGTGTCCAAATCCTTCCTCCTATATTCCTAAGTTACTAACGACC
AATTCAGACCACATGACATTCCTGCAAAGGGTCAAGAACATGCTCTACCCTCTGGCCCTG
TCCTACATTTGCCATACTTTTTCTGCCCCTTATGCAAGTCTTGCCTCTGAGCTTTTTCAG
AGAGAGGTGTCAGTGGTGGATCTTGTCAGCTATGCATCCGTGTGGCTGTTCCGAGGGGAC
TTTGTGATGGACTACCCCAGGCCGATCATGCCCAACATGGTCTTCATTGGGGGCATCAAC
TGTGCCAACGGGAAGCCACTATCTCAGGAATTTGAAGCCTACATTAATGCTTCTGGAGAA
CATGGAATTGTGGTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCT
ATGGCAATTGCTGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGA
ACCCGACCATCGAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGAT
CTGCTTGGTCACCCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTAT
GAAAGCATATGCAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGAC
AATGCAAAGCGCATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACT
TCTGAAGATTTAGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAAC
ATCATGCGCCTCTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTG
TTCTGGGTGGAGTTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCAC
GACCTCACCTGGTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTG
CTGACAGTGGCCTTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGG
AAAAAAGGGCGAGTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>